MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596253 | Name: JNJ-39758979 2HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNJ-39758979 2HCl is a histamine receptor H4 (HRH4) antagonist.

Chemical Structure

JNJ-39758979 2HCl
JNJ-39758979 2HCl
CAS#1620648-30-7

Theoretical Analysis

MedKoo Cat#: 596253

Name: JNJ-39758979 2HCl

CAS#: 1620648-30-7

Chemical Formula: C11H21Cl2N5

Exact Mass: 293.1174

Molecular Weight: 294.22

Elemental Analysis: C, 44.90; H, 7.19; Cl, 24.10; N, 23.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
JNJ-39758979 2HCl; JNJ-39758979 dihydrochloride;
IUPAC/Chemical Name
(R)-4-(3-aminopyrrolidin-1-yl)-6-isopropylpyrimidin-2-amine dihydrochloride
InChi Key
KXPWYAVIFCXPRW-YCBDHFTFSA-N
InChi Code
InChI=1S/C11H19N5.2ClH/c1-7(2)9-5-10(15-11(13)14-9)16-4-3-8(12)6-16;;/h5,7-8H,3-4,6,12H2,1-2H3,(H2,13,14,15);2*1H/t8-;;/m1../s1
SMILES Code
CC(c1nc(N)nc(N2CC[C@H](C2)N)c1)C.Cl.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 294.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kollmeier AP, Greenspan A, Xu XL, Silkoff PE, Barnathan E, Loza MJ, Jiang J, Zhou B, Chen B, Thurmond RL. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of an H(4) R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. Clin Exp Allergy. 2018 Apr 23. doi: 10.1111/cea.13154. [Epub ahead of print] PubMed PMID: 29682796. 2: Köchling H, Schaper K, Wilzopolski J, Gutzmer R, Werfel T, Bäumer W, Kietzmann M, Rossbach K. Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis. J Dermatol Sci. 2017 Aug;87(2):130-137. doi: 10.1016/j.jdermsci.2017.04.004. Epub 2017 Apr 21. PubMed PMID: 28495120. 3: Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP. Clinical Development of Histamine H(4) Receptor Antagonists. Handb Exp Pharmacol. 2017;241:301-320. doi: 10.1007/164_2016_130. Review. PubMed PMID: 28233185. 4: Sulaiman I, Lim JC, Soo HL, Stanslas J. Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. Pulm Pharmacol Ther. 2016 Oct;40:52-68. doi: 10.1016/j.pupt.2016.07.005. Epub 2016 Jul 22. Review. PubMed PMID: 27453494. 5: Murata Y, Song M, Kikuchi H, Hisamichi K, Xu XL, Greenspan A, Kato M, Chiou CF, Kato T, Guzzo C, Thurmond RL, Ohtsuki M, Furue M. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015 Feb;42(2):129-39. doi: 10.1111/1346-8138.12726. Epub 2014 Dec 9. PubMed PMID: 25491792. 6: Seifert R. Therapeutic efficacy of a H₄ receptor antagonist in humans: a milestone in histamine research. J Pharmacol Exp Ther. 2014 Jul;350(1):2-4. doi: 10.1124/jpet.114.215749comm. PubMed PMID: 24925898. 7: Kollmeier A, Francke K, Chen B, Dunford PJ, Greenspan AJ, Xia Y, Xu XL, Zhou B, Thurmond RL. The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J Pharmacol Exp Ther. 2014 Jul;350(1):181-7. doi: 10.1124/jpet.114.215749. Epub 2014 May 9. PubMed PMID: 24817035. 8: Thurmond RL, Chen B, Dunford PJ, Greenspan AJ, Karlsson L, La D, Ward P, Xu XL. Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979. J Pharmacol Exp Ther. 2014 May;349(2):176-84. doi: 10.1124/jpet.113.211714. Epub 2014 Feb 18. PubMed PMID: 24549371. 9: Savall BM, Chavez F, Tays K, Dunford PJ, Cowden JM, Hack MD, Wolin RL, Thurmond RL, Edwards JP. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists. J Med Chem. 2014 Mar 27;57(6):2429-39. doi: 10.1021/jm401727m. Epub 2014 Feb 21. PubMed PMID: 24495018.

View History

GSK706

GSK706